Introduction
============

Obstructive sleep apnea (OSA) is a prevalent yet underdiagnosed chronic disorder.^[@bib1]^ Together with daytime hypersomnolence, it is estimated to occur in approximately 14% of men and 5% of women aged 30--70 years.^[@bib2]^ OSA is associated with multiple comorbidities (including obesity), reduced quality of life, increased motor vehicle accidents and increased risk of cardiovascular mortality.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ Excess weight is considered to be the most important risk factor for OSA.^[@bib7],\ [@bib8]^ Moreover, the relationship between obesity and OSA appears to be bidirectional.^[@bib5]^ Approximately 60--70% of individuals with OSA are overweight,^[@bib9],\ [@bib10]^ and about 58% of moderate to severe OSA cases are attributable to excess weight.^[@bib8]^

Weight loss has been shown to reduce OSA severity and improve blood oxygen saturation and sleep architecture parameters, as well as self-reported quality of life.^[@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15]^ The beneficial effects of initial weight loss on OSA severity have been shown to persist over the long-term despite weight regain.^[@bib13],\ [@bib16],\ [@bib17]^ Current clinical practice guidelines recommend weight loss for adults with excess weight and OSA.^[@bib18],\ [@bib19]^

[@bib45]Nasal continuous positive airway pressure (CPAP) is considered to be the gold standard treatment for moderate to severe OSA. However, treatment adherence is often suboptimal (46--83% of individuals fail to adhere), and CPAP does not address the underlying pathophysiology (that is, excess weight) for overweight individuals with OSA.^[@bib20]^ For individuals with obesity and moderate or severe OSA who cannot or will not use CPAP, treatment options are limited.

Liraglutide, a glucagon-like peptide-1 (GLP-1) analog with a 97% homology to human GLP-1, is approved for the treatment of type 2 diabetes at once-daily doses up to 1.8 mg.^[@bib21]^ Liraglutide has recently received marketing approval for weight management at the 3.0 mg dose.^[@bib22],\ [@bib23],\ [@bib24]^ Liraglutide\'s weight loss mechanism in humans is through a reduction in appetite with a subsequent decrease in energy intake, not increased energy expenditure.^[@bib25]^

The aim of this 32-week randomized, controlled trial was to investigate whether liraglutide 3.0 mg would reduce the severity of OSA when compared with placebo (both as adjunct to a reduced-calorie diet and increased physical activity) in participants with obesity and moderate or severe OSA who were unwilling or unable to use CPAP therapy. Although both interventions were evaluated in conjunction with lifestyle modifications, they will be abbreviated as 'liraglutide\' and 'placebo\' hereafter. Liraglutide\'s weight loss efficacy, as well as the relationship between weight loss, sleep apnea end points and sleep/health-related quality of life, were also examined.

Materials and methods
=====================

Study overview
--------------

This 32-week randomized, double-blind, placebo-controlled parallel-group trial was conducted between June 2012 and June 2013 at 40 sites in the United States and Canada ([Figure 1](#fig1){ref-type="fig"}). The trial was conducted in accordance with the Declaration of Helsinki^[@bib26]^ and Good Clinical Practice Guidelines.^[@bib27]^ Local institutional review boards approved the trial protocol and all amendments. All participants provided written informed consent.

Participants
------------

The complete list of inclusion/exclusion criteria is provided in [Supplementary Table E1](#sup1){ref-type="supplementary-material"}. In brief, eligible individuals were men and women aged 18--64 years with a stable body weight (\<5% change during the previous 3 months) and body mass index (BMI) of ⩾30 kg m^−2^. Eligible individuals had to be diagnosed with moderate (apnea--hypopnea index (AHI) 15.0--29.9 events h^−1^) or severe (AHI ⩾30.0 events h^−1^) OSA and be unable or unwilling to use CPAP therapy. Individuals with central sleep apnea and/or type 1 or 2 diabetes were excluded from enrollment.

Intervention
------------

Eligible participants were randomly assigned 1:1 in a blinded, centralized manner (using a sponsor-provided telephone- or web-based system) to once-daily subcutaneous liraglutide or placebo. To reduce the likelihood of gastrointestinal symptoms,^[@bib22],\ [@bib23],\ [@bib24]^ liraglutide was started at the 0.6 mg day^−1^ dose and escalated in weekly 0.6-mg increments to 3.0 mg (week 4); [Figure 1](#fig1){ref-type="fig"}. The 3.0 mg dose was maintained for another 28 weeks. A placebo dose-volume equivalent was used to maintain blinding. In this double-blind trial, the participants, investigators/site personnel and sponsor were blinded to treatment assignments. All participants received counseling on diet and physical activity approximately every 4 weeks during treatment. Based on the individual total energy expenditure estimated by the investigator (using the World Health Organization estimates and an 'average\' physical activity factor of 1.3),^[@bib28]^ each participant was prescribed a daily energy intake 500 kcal below the aforementioned estimate. The diet prescribed approximately 30% of energy from fat, 20% from protein and 50% from carbohydrates. In addition, participants were advised to increase their physical activity to at least 150 min per week. Adherence to lifestyle modifications was encouraged through the distribution of 3-day food diaries (every 5--8 weeks) and pedometers, but was not assessed as an end point.

Outcome measures
----------------

The primary efficacy end point was change in AHI (using the American Academy of Sleep Medicine\'s recommended 2007 definition, with hypopnea scoring requiring ⩾30% reduction in nasal pressure signal excursions from baseline and ⩾4% desaturation from pre-event baseline)^[@bib29]^ from baseline to week 32. Key secondary efficacy end points included changes from baseline to week 32 in OSA severity category, blood oxygen saturation parameters (lowest oxygen saturation, percentage of time with oxygen saturation \<90% and oxygen desaturation ⩾4% index), sleep architecture parameters (total sleep time, wake time after sleep onset, proportion of sleep spent in supine position and sleep stage distribution), body weight-related parameters (fasting body weight, proportion of participants losing ⩾5% or \>10% of baseline fasting body weight, BMI, waist and neck circumference), glycemic parameters (HbA~1c~ and fasting plasma glucose), vital signs (systolic blood pressure (SBP) and diastolic blood pressure, pulse), fasting lipids (high-density lipoprotein, low-density lipoprotein, very-low-density lipoprotein, and total cholesterol and triglycerides), cardiovascular biomarkers (high-sensitivity C-reactive protein and urinary albumin:creatinine ratio), daytime sleepiness (Epworth Sleepiness Scale) and self-reported quality of life (Functional Outcomes of Sleep Questionnaire (FOSQ) and 36-item Short-Form (SF-36) health status survey). Questionnaire total score can range from 0 to 24, with a lower score indicating a lower propensity for daytime sleepiness.^[@bib30]^ FOSQ total score can range from 5 to 20, with a higher score indicating less functional impairment.^[@bib31]^ The SF-36 scores can range from 0 to 100, with higher scores indicating a better quality of life.^[@bib32]^

Polysomnographic (PSG) assessments (including AHI, blood oxygen saturation parameters, sleep architecture parameters and nocturnal heart rate) were performed during overnight clinic stays at weeks −1 (screening), 12 and 32, and data were scored centrally by Clinilabs (New York, NY, USA). Body weight-related parameters and vital signs were assessed at every visit from week 0 to 32. After randomization, glycemic parameters, fasting lipids, cardiovascular biomarkers and quality of life were assessed at weeks 0, 12 and 32; fasting plasma glucose was also assessed at weeks 4, 8, 20 and 28.

Safety assessments included adverse events (AEs), standard laboratory tests, physical examinations, electrocardiograms and mental health (Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale). Specific attention was given to certain types of AEs, including those related to obesity and/or weight loss or side-effects relevant to the GLP-1 receptor agonist drug class ([Supplementary Table E2](#sup1){ref-type="supplementary-material"}).

Statistical analysis
--------------------

The sample size was calculated using a two-sided *t*-test with a significance level of 5%. A sample size of 308 was estimated to provide a ⩾85% power to detect a treatment difference of 6 events h^−1^ for the primary end point, assuming a s.d. of 17 events h^−1^ (based on previous publications). The sample size calculation was also based on the assumption that 5% of participants would withdraw before trial completion without any post-baseline data for the primary analysis (see next paragraph) of the primary end point. In fact, 7% of participants withdrew from the trial without providing any post-baseline data for the primary end point ([Supplementary Methods](#sup1){ref-type="supplementary-material"} and [Supplementary Table E3](#sup1){ref-type="supplementary-material"}).

The efficacy analyses were performed on the data from the full analysis set, which included all randomized participants. The safety analysis set included all randomized participants who were exposed to ⩾1 dose(s) of trial drug. The last observation carried forward imputation method was pre-specified for primary and secondary analyses. A detailed description of the imputation approach used for the primary end point is provided in the [Supplementary Methods](#sup1){ref-type="supplementary-material"}. The presented results are based on last observation carried forward imputation unless otherwise noted. The robustness of the primary analysis was investigated by multiple sensitivity analyses using other methods for handling missing data ([Supplementary Table E3](#sup1){ref-type="supplementary-material"}).

Continuous end points were analyzed using a pre-specified analysis of covariance model with treatment, gender and country as fixed effects and baseline BMI, age and value at baseline as covariates. The null hypothesis was rejected on a 5% level if the two-sided 95% confidence interval (CI) of the treatment difference excluded 0. Pre-specified analyses of categorical end points were performed using logistic regression, with the same fixed effects and covariates as the analysis of covariance. Exploratory analyses of the influence of weight loss on selected end points were conducted *post hoc. Post hoc* analysis of covariance models also included a weight change (% or kg) covariate and examined its interactions with other effects (for example, OSA severity category at baseline). No adjustment for multiple testing was applied to the secondary analyses and the results should be evaluated accordingly.

Unless otherwise specified, mean changes from baseline are presented as observed means±s.d. (or s.e.) in the main manuscript. Model-estimated mean changes from baseline are presented in the [Supplementary Table E4](#sup1){ref-type="supplementary-material"}. Safety data were summarized descriptively. Statistical analyses were performed with SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Trial population
----------------

Of the 359 randomized participants, 276 (liraglutide: 134 (74%), placebo: 142 (79%)) completed the trial ([Figure 2](#fig2){ref-type="fig"}). A higher proportion of participants withdrew because of AEs in the liraglutide than in the placebo group (12% vs 3%); gastrointestinal AEs most commonly led to trial withdrawal in the liraglutide group. More participants in the placebo group than in the liraglutide group withdrew consent to participate (11% vs 7%).

Baseline characteristics of randomized participants were similar between the two treatment groups ([Table 1](#tbl1){ref-type="table"}).^[@bib28],\ [@bib33]^ Consistent with the greater prevalence of OSA in males, \>70% of trial participants were male. The majority of participants had severe OSA (\~67%). The mean baseline AHI of approximately 49 events h^−1^ revealed the high severity of the disease. Approximately half of the participants with moderate OSA were females, whereas participants with severe OSA were predominantly males (\~80%). Generally, participants with severe OSA were heavier, and more had comorbidities than those with moderate OSA.

Polysomnography end points
--------------------------

In both treatment groups, most of the reduction in mean AHI occurred by week 12, with minimal changes thereafter ([Figure 3a](#fig3){ref-type="fig"}). At week 32, the mean reduction in AHI with liraglutide was statistically significantly greater compared with placebo (−12.2±1.8 vs −6.1±2.0 events h^−1^; estimated treatment difference: −6.1 events h^−1^ (95% CI, −11.0 to −1.2), *P*=0.015) ([Figure 4a](#fig4){ref-type="fig"} and [Supplementary Table E4](#sup1){ref-type="supplementary-material"}). The robustness of the primary analysis findings was confirmed with several sensitivity analyses ([Supplementary Table E3](#sup1){ref-type="supplementary-material"}). The treatment effect on AHI did not depend on participants\' gender, baseline BMI, or OSA severity category (*P*\>0.05 for interaction with treatment for all). However, participants with severe OSA at baseline experienced greater mean reduction in AHI in both treatment groups. The majority of participants in both treatment groups did not experience improvement/worsening of their baseline OSA severity category after 32 weeks ([Supplementary Figure E1](#sup1){ref-type="supplementary-material"}, panel A). However, there was a trend for more liraglutide-treated than placebo-treated participants to no longer meet the diagnostic criteria for OSA (that is, AHI \<5 events h^−1^) (5.4% vs 1.2%, respectively; odds ratio (OR) 4.4 (95% CI, 0.9--21.0), *P*=0.07) or experience a 50% reduction in their baseline AHI score (31.5% vs 21.7%, respectively, OR 1.6 (95% CI, 1.0--2.7), *P*=0.05). The changes in oxygen saturation and sleep architecture parameters presented in [Figure 4a](#fig4){ref-type="fig"} and [Supplementary Table E4](#sup1){ref-type="supplementary-material"} did not differ significantly between the liraglutide and placebo groups. In addition, no notable changes from baseline in sleep stage distribution were observed at week 32 (end point was not analyzed statistically). The change in the proportion of sleep time spent in the supine position after 32 weeks did not differ significantly between treatment groups (*P*=0.20).

Body weight and related end points
----------------------------------

Mean body weight decreased continuously in the liraglutide 3.0 mg group over the 32 weeks ([Figure 3b](#fig3){ref-type="fig"}). In the placebo group, the mean weight loss curve appeared to plateau around week 12. At week 32, the mean weight loss was significantly greater with liraglutide than with placebo (−5.7±0.4% vs −1.6±0.3%, estimated treatment difference: −4.2%, (95% CI, −5.2 to −3.1%), *P*\<0.0001; [Figure 4b](#fig4){ref-type="fig"} and [Supplementary Table E4](#sup1){ref-type="supplementary-material"}). Greater proportions of liraglutide- versus placebo-treated participants lost either ⩾5% (46.3% vs 18.5%, OR: 3.9 (95% CI, 2.4--6.4), *P*\<0.0001) or \>10% (23.4% vs 1.7%, OR: 19.0 (95% CI, 5.7--63.1), *P*\<0.0001) of baseline body weight at week 32. Consistent with the greater weight loss effect, significantly greater reductions in BMI, waist and neck circumference were also observed with liraglutide compared with placebo.

Glycemic control and cardiometabolic parameters
-----------------------------------------------

Liraglutide 3.0 mg produced significantly greater reductions from baseline in HbA~1c~ and fasting plasma glucose than placebo at week 32 ([Figure 4b](#fig4){ref-type="fig"} and [Supplementary Table E4](#sup1){ref-type="supplementary-material"}). Liraglutide also significantly reduced SBP compared with placebo, but had no significant effect on diastolic blood pressure. No statistically significant improvements in fasting lipids or the urinary albumin:creatinine ratio were observed with liraglutide compared with placebo. The reduction in high-sensitivity C-reactive protein with liraglutide was of borderline significance versus placebo (*P*=0.05).

Sleep/health-related quality of life
------------------------------------

Significantly greater improvements with liraglutide 3.0 mg than placebo were observed for the 'general health\' domain of the SF-36 (*P*=0.0426) and the 'activity level\' domain of the FOSQ (*P*=0.015). The remaining total and individual domain scores on the three questionnaires (Epworth Sleepiness Scale (ESS), FOSQ and SF-36) did not differ significantly between groups ([Figure 4a](#fig4){ref-type="fig"} and [Supplementary Table E4](#sup1){ref-type="supplementary-material"}).

Relationship between weight loss and selected sleep-related end points
----------------------------------------------------------------------

Treatment assignment, independent of weight loss, did not significantly affect the change from baseline in AHI (*P*=0.82); that is, the effect of treatment was mediated by weight loss in both groups. In both treatment groups, greater weight loss was significantly associated with greater reduction in AHI ([Figure 3c](#fig3){ref-type="fig"}). Similarly, larger proportions of participants tended to improve their OSA severity category and lesser proportions tended to worsen their OSA severity category with greater weight loss ([Supplementary Figure E1](#sup1){ref-type="supplementary-material"}, panels B and C). In *post hoc* analysis, the reduction in AHI per 1% (or 1 kg) weight loss depended on baseline AHI, with reductions of 0.7 (0.7), 1.4 (1.3) and 2.8 (2.2) events h^−1^ for baseline AHI cohorts \<30, 30--59 and ⩾60 events h^−1^, respectively (*P*\<0.001, both groups). Greater weight loss at the end of the trial was also significantly associated with greater end-of-trial improvements in end points related to oxygen saturation, sleep architecture and total scores on Epworth Sleepiness Scale and FOSQ (*P*\<0.01 for all) ([Supplementary Figure E2](#sup1){ref-type="supplementary-material"}).

Safety
------

More participants reported AEs with liraglutide (80.1%) than with placebo (69.3%), driven primarily by the greater prevalence of gastrointestinal AEs with liraglutide (mainly nausea). Gastrointestinal AEs were mostly mild or moderate in severity and transient, occurring mainly within the initial 8 weeks of treatment. Most participants experiencing AEs reported events that were either mild (liraglutide: 69.9%, placebo: 57.5%) or moderate (liraglutide: 50.0%, placebo: 36.3%) in severity. No deaths occurred. Identical proportions of participants in both groups (3.4%) reported serious AEs ([Table 2](#tbl2){ref-type="table"}). Overall, serious AEs occurred as single cases and there was no notable pattern of distribution with respect to the system organ class. Based on the low number of reported special-focus events in both groups, no clear patterns of distribution or differences between treatments were identified. No events of pancreatitis or medullary thyroid carcinoma were reported. In total, two AEs of cholelithiasis (one serious) were reported with liraglutide and one serious AE of cholecystitis was reported with placebo. Amylase and lipase activity and calcitonin are described in the [Supplementary Results](#sup1){ref-type="supplementary-material"}.

Similar to previous findings with GLP-1 receptor agonists, a significantly greater increase in mean resting pulse was seen with liraglutide compared with placebo at week 32 (1.6±0.8 vs 0.8±0.8 beats min^−1^, estimated treatment difference 2.1 beats min^−1^ (95% CI, 0.3--4.0), *P*=0.0256). Normal physiological decline in nocturnal heart rate was observed in both treatment groups during the 8- h PSG assessment, but less so with liraglutide ([Supplementary Figure E3](#sup1){ref-type="supplementary-material"}). Compared with previous findings with liraglutide doses up to 1.8 mg in diabetes, no new safety issues with liraglutide 3.0 mg were identified during clinical laboratory evaluation, physical examinations and electrocardiogram assessment. No notable differences between liraglutide and placebo were observed during mental health evaluations with Patient Health Questionnaire-9 and Columbia Suicide Severity Rating Scale.

Discussion
==========

This trial examined the effect of weight loss on OSA severity in participants with obesity and moderate/severe OSA who were unable or unwilling to use CPAP therapy. After 32 weeks of treatment, a statistically significantly greater reduction in mean AHI was seen with liraglutide 3.0 mg compared with placebo, both adjunctive to diet and exercise counseling. Accompanying the AHI reduction, consistent trends for improvement were also seen with liraglutide versus placebo across oxygen saturation, sleep architecture and sleep/health-related quality of life end points. Improvements in OSA end points were related to the degree of weight loss at the end of the study, with greater improvement seen with greater weight loss. This observation is in line with those from several other randomized, controlled studies in patients with OSA, irrespective of whether weight loss was induced by lifestyle intervention, pharmacotherapy or surgery.^[@bib11],\ [@bib12],\ [@bib14],\ [@bib34],\ [@bib35]^ The effect of weight loss on AHI appeared to be most pronounced in participants with severe OSA at baseline, an observation also previously reported in other weight loss studies in participants with obesity and OSA.^[@bib11],\ [@bib13]^ Although the present trial was not specifically designed to detect treatment differences for shifts in OSA severity categories, greater percentages of participants improved severity category with greater weight loss in both groups. At week 32, weight loss with liraglutide had not plateaued. Thus, it is possible that further weight loss-related improvement in AHI would have been seen with longer liraglutide treatment duration. The precise clinical significance of the 12 events h^−1^ mean reduction in AHI with liraglutide is unclear, but consistent positive changes in supportive secondary end points related to sleep apnea and cardiovascular risk factors indicate an overall trend toward improvement. Although no significant improvements in supportive sleep apnea end points were seen in this population with mainly severe disease (baseline AHI \~49 events h^−1^), the statistical/clinical significance of AHI reduction with liraglutide may become more apparent in patients with a less severe form of the disease (that is, mild to moderate). This is a subject for further studies.

Individuals with OSA often have a co-aggregation of other adverse conditions (that is, obesity, metabolic syndrome, dysglycemia/diabetes) that predispose them to increased cardiovascular risk.^[@bib5]^ This clustering of risk factors was exemplified in the present trial population; in addition to moderate/severe OSA and obesity, 42% of participants had hypertension, 33% had dyslipidemia and 63% had prediabetes (classification was based on the HbA~1c~ and fasting plasma glucose criteria of the American Diabetes Association 2010 definition)^[@bib33]^ at baseline; individuals with diabetes were excluded from the trial. In addition to greater reductions in AHI, participants treated with liraglutide 3.0 mg also experienced significantly greater improvements in other measures of cardiovascular risk, including SBP and blood glucose, both of which are well-described effects of liraglutide treatment in participants with and without diabetes.^[@bib21],\ [@bib36],\ [@bib37]^ SBP reductions of a similar magnitude to that observed with liraglutide 3.0 mg in this trial (3.4 mm Hg reduction from baseline) have been associated with lower cardiovascular risk/mortality.^[@bib38],\ [@bib39]^ Consistent with observations for the GLP-1 receptor agonist drug class, treatment with liraglutide increased mean resting heart rate by 2 beats min^−1^ compared with placebo in this trial.^[@bib40],\ [@bib41]^ As participants with OSA are characterized by increased sympathetic tone,^[@bib42],\ [@bib43]^ it is reassuring that in this trial the increase in heart rate was similar or smaller and the reduction in SBP was greater than those previously observed with liraglutide 3.0 mg in participants without OSA.^[@bib37],\ [@bib44]^ The long-term clinical effects of the increase in heart rate have not been established. Results from the cardiovascular outcomes trial with liraglutide in patients with type 2 diabetes mellitus (LEADER) indicate liraglutide treatment is associated with a statistically significant reduction in cardiovascular risk (assessed using a composite outcome (first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke during the 3.5--5 year trial period)).^[@bib45]^

The safety profile of liraglutide 3.0 mg in this trial was consistent with that previously observed with liraglutide doses up to 1.8 mg in diabetes and with liraglutide 3.0 mg in the other trials within the weight management program.^[@bib21],\ [@bib37],\ [@bib46]^ No new safety issues were identified. As typically observed with GLP-1 receptor agonists,^[@bib47],\ [@bib48]^ transient gastrointestinal AEs (mainly nausea) occurred more frequently with liraglutide 3.0 mg, but generally subsided after the initial 8 weeks of treatment.

The strengths of the study include its sample size of approximately 360 participants. In addition, meticulous recording of PSG data at specialized sleep sites and the central reading of all PSG results increased data reliability. The study was limited by its 32-week duration, which precluded the achievement of maximum weight loss and observation of effect durability on OSA-related parameters and body weight. Although power was maintained, approximately 23% of participants across both groups withdrew before trial completion. This attrition rate is reasonable given the difficulty of retaining patients in sleep apnea trials (because of the discomfort/burden associated with overnight PSG assessments), and corresponds to that seen in another OSA trial with a large sample size.^[@bib11]^ Importantly, the findings for the primary end point were generally consistent across various methods of handling missing data.

Conclusion
==========

In participants with obesity and moderate or severe OSA, 32 weeks of treatment with liraglutide 3.0 mg (combined with lifestyle modification) produced significantly greater reductions in AHI and improved several other measures of cardiovascular risk, including body weight, blood glucose and SBP, when compared with placebo (that is, lifestyle modifications alone). Greater weight loss led to greater improvements in AHI and other sleep-related end points. This study suggests that liraglutide 3.0 mg in conjunction with a diet and exercise regimen may be useful as a weight management component of a comprehensive therapeutic approach for OSA management. Given its range of beneficial pharmacodynamic effects, liraglutide 3.0 mg may also be a useful tool in individuals already on CPAP treatment.
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![Trial design. EOT, end of treatment; FU, follow-up.](ijo201652f1){#fig1}

![Trial flow. Participants could be ineligible for trial enrollment because of more than one inclusion/exclusion criterion. \*Participants did not receive any trial drug and withdrew from the trial. \*\*Non-compliance with the trial protocol included, but was not limited to, incorrect handling of trial product, non-compliance to visit schedule and dietary advice and non-completion of trial-related questionnaires.](ijo201652f2){#fig2}

![Change in AHI and body weight over 32 weeks of treatment and the relationship between weight loss and change in AHI. (**a**) Change in AHI during the treatment period. (**b**) Change in body weight during the treatment period. (**c**) Relationship between weight loss and change in AHI. (**a**, **b**) Data are observed means±s.e. from the full analysis set (FAS). The last observation carried forward (LOCF) value is shown at week 32. In **c**, data are mean±s.e. from the FAS, LOCF. Weight gain or loss category represents the change in body weight (%) from baseline after 32 weeks of treatment. PSG assessments were performed at weeks --1 (baseline), 12 and 32. For PSG-derived parameters (that is, AHI), participants without any post-baseline PSG assessments were excluded from the analyses. For the body weight parameter, participants without any post-baseline measurements were excluded from the analyses; in addition, participants without baseline measurements were excluded from the change from baseline analyses. *N*, number of participants; *n*, number of participants in each weight loss category; WG, weight gain; WL, weight loss.](ijo201652f3){#fig3}

![Changes in PSG, quality of life and cardiometabolic end points after 32 weeks of treatment. (**a**) Changes in PSG and quality of life end points. (**b**) Changes in cardiometabolic end points. Forest plots show estimated treatment differences (ETDs)/odds ratios and 95% CIs. Data are from the full analysis set (last observation carried forward (LOCF)). Data at baseline are mean±s.d. For PSG-derived parameters, participants without any post-baseline PSG assessments were excluded from the analyses. For quality of life and cardiometabolic parameters, participants without any post-baseline measurements were excluded from the analyses; in addition, participants without baseline measurements were excluded from the change from baseline analyses. Improvement/worsening refer to the changes from baseline with liraglutide 3.0 mg relative to those with placebo. DBP, diastolic blood pressure; ESS, Epworth Sleepiness Scale; FPG, fasting plasma glucose; I, improvement; ODI, oxygen desaturation index; SpO~2~, oxygen saturation; WASO, wake time after sleep onset.](ijo201652f4){#fig4}

###### Baseline characteristics of randomized trial participants

  *Characteristic*                                     *Liraglutide 3.0 mg (*N=*180)*   *Placebo (*N=*179)*
  --------------------------------------------------- -------------------------------- ---------------------
  *Sex*---N *(%)*                                                                      
   Female                                                        51 (28.3)                   50 (27.9)
   Male                                                          129 (71.7)                 129 (72.1)
                                                                                       
  Age---years                                                     48.6±9.9                   48.4±9.5
                                                                                       
  *Race*[a](#t1-fn2){ref-type="fn"}---N *(%)*                                          
   White                                                         130 (72.2)                 135 (75.4)
   Black or African American                                     33 (18.3)                   36 (20.1)
   Asian                                                          13 (7.2)                    3 (1.7)
   Native Hawaiian or other Pacific Islander                      1 (0.6)                     2 (1.1)
   Other                                                          3 (1.7)                     3 (1.7)
                                                                                       
  Hispanic/Latino ethnicity---*N* (%)                            19 (10.6)                   24 (13.4)
                                                                                       
  *OSA severity category*---N *(%)*                                                    
   Moderate (AHI 15--29.9 events/h)                              60 (33.3)                   58 (32.4)
    Females/Males---%                                            45.0/55.0                   44.8/55.2
   Severe (AHI⩾30 events/h)                                      120 (66.7)                 121 (67.6)
    Females/Males---%                                            20.0/80.0                   19.8/80.2
                                                                                       
  AHI[b](#t1-fn3){ref-type="fn"}---events/h                      49.0±27.5                   49.3±27.5
  Waist circumference---cm                                       122.3±14.5                 122.7±14.9
  Neck circumference---cm                                         44.5±4.5                   44.2±4.6
  Pulse---beats/min                                               73.6±9.1                   71.5±9.9
  Body-mass index[c](#t1-fn4){ref-type="fn"}                      38.9±6.4                   39.4±7.4
                                                                                       
  *Body-mass index categories*---N *(%)*                                               
   27--29.9, overweight                                              0                        1 (0.6)
   30--34.9, obese class I                                       58 (32.2)                   51 (28.5)
   35--39.9, obese class II                                      59 (32.8)                   62 (34.6)
   ⩾40, obese class III                                          63 (35.0)                   65 (36.3)
                                                                                       
  *Cholesterol*---*mg/dl*                                                              
   Total                                                         190.4±20.2                 191.5±18.6
   LDL                                                           111.6±28.9                 111.4±26.8
   HDL                                                           45.7±22.8                   44.5±28.6
   VLDL                                                          28.0±53.3                   28.8±64.7
                                                                                       
  Triglycerides---mg/dl                                          140.3±55.9                 144.7±83.5
  Urinary albumin:creatinine ratio (mg/g)                        3.4±286.5                   3.7±293.2
                                                                                       
  Prediabetes---*N* (%)[d](#t1-fn5){ref-type="fn"}               115 (63.9)                 112 (62.6)
  Dyslipidemia---*N* (%)[e](#t1-fn6){ref-type="fn"}              65 (36.1)                   55 (30.7)
  Hypertension---*N* (%)[e](#t1-fn6){ref-type="fn"}              75 (41.7)                   77 (43.0)
                                                                                       
  Depression or mood disorders---*N* (%)                         29 (16.1)                   30 (16.8)

Abbreviations: AHI, apnea-hypopnea index; CV, coefficient of variation; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OSA, obstructive sleep apnea; VLDL, very-low-density lipoprotein. Values are means±s.d., unless otherwise noted. For lipids and cardiovascular biomarkers, values are geometric means±CV. To convert values for cholesterol to mmol/L, multiply by 0.0259.

Race was self-reported based on categories defined by the Sponsor.

Definitions of apnea and hypopnea from the 2007 American Academy of Sleep Medicine Manual for the Scoring of Sleep and Associated Events were used.^[@bib29]^

The body-mass index is the weight in kilograms divided by the square of the height in meters.

Prediabetes was defined based on the HbA~1c~ and FPG criteria of the ADA 2010 definition.^[@bib33]^

Dyslipidemia and hypertension at baseline were identified by a MedDRA preferred term search.

###### Adverse events occurring in 5% or more of participants in either group and serious adverse events

  *Event*[a](#t2-fn3){ref-type="fn"}           *Liraglutide 3.0 mg (*N=*176)*    *Placebo (*N=*179)*                            
  -------------------------------------------- -------------------------------- --------------------- ------- ----------- ----- -------
  *Adverse events in 5% or more individuals*   117 (66.5)                                278           310.5  84 (46.9)    152   158.4
   Nausea                                      47 (26.7)                                 59            65.9   12 (6.7)     14    14.6
   Diarrhea                                    29 (16.5)                                 38            42.4   14 (7.8)     17    17.7
   Headache                                    25 (14.2)                                 26            29.0   20 (11.2)    23    24.0
   Constipation                                21 (11.9)                                 26            29.0   6 (3.4)       7     7.3
   Upper respiratory tract infection           18 (10.2)                                 25            27.9   19 (10.6)    25    26.0
   Dyspepsia                                   15 (8.5)                                  20            22.3   2 (1.1)       2     2.1
   Nasopharyngitis                             15 (8.5)                                  19            21.2   18 (10.1)    20    20.8
   Vomiting                                    13 (7.4)                                  16            17.9   5 (2.8)       5     5.2
   Gastroesophageal reflux disease             10 (5.7)                                  11            12.3   1 (0.6)       1     1.0
   Influenza                                   9 (5.1)                                   12            13.4   9 (5.0)       9     9.4
   Lipase increased                            9 (5.1)                                   11            12.3   5 (2.8)       6     6.3
   Arthralgia                                  7 (4.0)                                    7             7.8   9 (5.0)       9     9.4
   Injection site hematoma                     7 (4.0)                                    8             8.9   13 (7.3)     14    14.6
  *Serious adverse events*                     6 (3.4)                                   14            15.6   6 (3.4)       9     9.4
   Angina pectoris                             2 (1.1)                                    3             3.4   0             0      0
   Anxiety                                     1 (0.6)                                    1             1.1   0             0      0
   Cholelithiasis                              1 (0.6)                                    1             1.1   0             0      0
   Coronary revascularization                  1 (0.6)                                    1             1.1   1 (0.6)       1     1.0
   Dehydration                                 1 (0.6)                                    1             1.1   0             0      0
   Depression suicidal                         1 (0.6)                                    1             1.1   0             0      0
   Oropharyngeal swelling                      1 (0.6)                                    1             1.1   0             0      0
   Pneumonia                                   1 (0.6)                                    1             1.1   0             0      0
   Procedural pain                             1 (0.6)                                    1             1.1   0             0      0
   Sinus arrest                                1 (0.6)                                    1             1.1   0             0      0
   Sleep apnea syndrome                        1 (0.6)                                    1             1.1   0             0      0
   Spinal fracture                             1 (0.6)                                    1             1.1   0             0      0
   Angina unstable                             0                                          0              0    1 (0.6)       1     1.0
   Bone lesion                                 0                                          0              0    1 (0.6)       1     1.0
   Cholecystitis                               0                                          0              0    1 (0.6)       1     1.0
   Gastroesophageal reflux disease             0                                          0              0    1 (0.6)       1     1.0
   Myocardial infarction                       0                                          0              0    1 (0.6)       1     1.0
   Nightmare                                   0                                          0              0    1 (0.6)       1     1.0
   Obstruction gastric                         0                                          0              0    1 (0.6)       1     1.0
   Prostate cancer                             0                                          0              0    1 (0.6)       1     1.0

Abbreviations: E, number of adverse events; *N*, number of participants; R, event rate per 100 exposure years; %, the proportion of participants reporting the adverse event.

Data are based on the Safety Analysis Set.

Adverse events are presented by preferred term. Adverse events are treatment-emergent, defined as an event that has onset date on or after the first day of randomized treatment and no later than 14 days after the last day of randomized treatment. A participant could experience more than one adverse event.

[^1]: A complete list of investigators in the Satiety and Clinical Adiposity---Liraglutide Evidence in non-diabetic and diabetic individuals (SCALE) study group is provided in the Online-Only Supplement.
